Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults.
作者： Christian Laurent , Ndeye Fatou Ngom Gueye , Cheikh Tidiane Ndour , Pape Mandoumb?? Gueye , Martin Diouf
DOI: 10.1097/00126334-200501010-00003
关键词:
摘要: Objectives: To assess the long-term survival, as well as the immunologic and virologic effectiveness, adherence, and drug resistance, in HIV-infected patients receiving highly active …
lww.com
sci-hub.se 参考文章(13)
Besigin Tonwe-Gold, Eugène Messou, Alain Daudié, François Rouet, Thérèse N'Dri-Yoman, Siaka Touré, Christine Danel, Catherine Seyler, Xavier Anglaret, Roger Salamon, Nicole Dakoury-Dogbo, André Inwoley, Chantal Maurice, Nafissa Diakité, Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antiviral Therapy. ,vol. 8, pp. 385- 393 ,(2003)
K. Van Vaerenbergh, T. Harrer, J.-C. Schmit, A. Carbonez, E. Fontaine, M. Kurowski, M. Grünke, P. Löw, A. Rascu, B. Schmidt, M. Schmitt, I. Thoelen, H. Walter, K. Van Laethem, M. Van Ranst, J. Desmyter, E. De Clercq, A.-M. Vandamme, Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Research and Human Retroviruses. ,vol. 18, pp. 419- 426 ,(2002) , 10.1089/088922202753614182
Isabelle Lanièce, Mounirou Ciss, Alice Desclaux, Karim Diop, Fatou Mbodj, Barra Ndiaye, Omar Sylla, Eric Delaporte, Ibrahima Ndoye, None, Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. ,vol. 17, ,(2003) , 10.1097/00002030-200317003-00014
Alice Desclaux, Mounirou Ciss, Bernard Taverne, Papa S. Sow, Marc Egrot, Mame A. Faye, Isabelle Lanièce, Omar Sylla, Eric Delaporte, Ibrahima Ndoye, Access to antiretroviral drugs and AIDS management in Senegal. AIDS. ,vol. 17, ,(2003) , 10.1097/00002030-200317003-00013
Gaston Djomand, Thierry Roels, Tedd Ellerbrock, Debra Hanson, Fabien Diomande, Bondo Monga, Chantal Maurice, John Nkengasong, Regina Konan-Koko, Auguste Kadio, Stefan Wiktor, Eve Lackritz, Joseph Saba, Terence Chorba, Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire AIDS. ,vol. 17, ,(2003) , 10.1097/00002030-200317003-00002
Jean Servais, Jean-Claude Schmit, Vic Arendt, Christine Lambert, Thérèse Staub, Isabelle Robert, Elodie Fontaine, Jean-Marc Plesséria, Catherine Burgy, Pierre Kirpach, François Schneider, Robert Hemmer, Three-Year Effectiveness of Highly Active Antiretroviral Treatment in the Luxembourg HIV Cohort Hiv Clinical Trials. ,vol. 1, pp. 17- 24 ,(2000) , 10.1310/FXCQ-1WET-CAH0-X62P
Paul J Weidle, Samuel Malamba, Raymond Mwebaze, Catherine Sozi, Gideon Rukundo, Robert Downing, Debra Hanson, Dorothy Ochola, Peter Mugyenyi, Jonathan Mermin, Badara Samb, Eve Lackritz, Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance The Lancet. ,vol. 360, pp. 34- 40 ,(2002) , 10.1016/S0140-6736(02)09330-3
Laurence Vergne, Coumba Touré Kane, Christian Laurent, Ndella Diakhaté, Ndeye Fatou Ngom Gueye, Pape Mandoumbé Gueye, Papa Salif Sow, Mame Awa Faye, Florian Liégeois, Adama Ndir, Isabelle Lanièce, Martine Peeters, Ibrahima Ndoye, Souleymane Mboup, Eric Delaporte, Low rate of genotypic Hiv-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy AIDS. ,vol. 17, ,(2003) , 10.1097/00002030-200317003-00005
Roland Landman, Ricarda Schiemann, Safiatou Thiam, Muriel Vray, Anna Canestri, Souleymane Mboup, Coumba Toure Kane, Eric Delaporte, Papa Salif Sow, Mame Awa Faye, Mandoumbe Gueye, Gilles Peytavin, Cecile Dalban, Pierre-Marie Girard, Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. ,vol. 17, pp. 1017- 1022 ,(2003) , 10.1097/00002030-200305020-00010
Alexander J. Frater, David T. Dunn, Alison J. Beardall, Koya Ariyoshi, John R. Clarke, Myra O. McClure, Jonathan N. Weber, Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. ,vol. 16, pp. 1139- 1146 ,(2002) , 10.1097/00002030-200205240-00007